Skip to content
Dosage GuideResearch Reference

Bivalirudin Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Bivalirudin. All information is for educational purposes only.

Quick Answer

Bivalirudin dosage is weight-based, administered intravenously. For PCI, a typical regimen is a 0.75 mg/kg bolus followed by a 1.75 mg/kg/hr infusion during the procedure. In HIT patients, lower doses (0.15-0.2 mg/kg/hr) are used. Renal impairment requires dose adjustments. ACT monitoring may be necessary to guide dosing during PCI.

→ Bivalirudin Benefits→ Bivalirudin Side Effects→ Full Bivalirudin Profile
Table of Contents

Standard Dosage Range

Research dosing range: 0.75 mg/kg bolus + 1.75 mg/kg/hr infusion (PCI); 0.15-0.2 mg/kg/hr infusion (HIT)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Percutaneous Coronary Intervention (PCI)

0.75 mg/kg bolus, 1.75 mg/kg/hr infusionSingle bolus, continuous infusion during procedure
Duration

During PCI, up to 4 hours post-procedure

FDA-approved. Check ACT 5 min after bolus; give additional 0.3 mg/kg bolus if ACT <225 sec. Post-PCI infusion (0.2 mg/kg/hr) may be continued for up to 20 hours if needed.

Heparin-Induced Thrombocytopenia (HIT)

0.15-0.2 mg/kg/hr infusionContinuous infusion
Duration

Until platelet recovery

Off-label use. Lower doses compared to PCI. Monitor platelet count daily. Dose reduction may be needed in renal impairment.

Renal Impairment (PCI)

0.75 mg/kg bolus, 1.0 mg/kg/hr infusionSingle bolus, continuous infusion during procedure
Duration

During PCI, up to 4 hours post-procedure

Reduce infusion rate in CrCl <30 mL/min. Monitor ACT closely. Dialysis-dependent patients require further dose reduction.

Acute Myocardial Infarction (AMI)

0.75 mg/kg bolus, 1.75 mg/kg/hr infusionSingle bolus, continuous infusion during procedure
Duration

During PCI, up to 4 hours post-procedure

Used as an alternative to heparin. May reduce bleeding risk. Monitor for stent thrombosis.

Timing & Frequency

Bivalirudin is administered intravenously immediately before and during the PCI procedure or continuously in HIT patients until platelet recovery. Due to its short half-life, the anticoagulant effect dissipates rapidly after stopping the infusion.

Cycle Guidance

Bivalirudin is typically used as a single administration during PCI or as a continuous infusion until platelet recovery in HIT. Cycling is not applicable due to its short half-life and clinical use case.

Reconstitution Reference

Quick reference for reconstituting Bivalirudin. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial Size250 mg per vial
BAC Water Volume5 mL sterile water for injection for a concentration of 50 mg/mL
Concentration & DrawAt 50 mg/mL: Varies based on patient weight. Refer to package insert for detailed instructions.
StorageStore unopened vials at controlled room temperature (20-25°C). Reconstituted solution is stable for 24 hours at room temperature.
StabilityUnopened vials are stable until the expiration date. Reconstituted solutions should be used within 24 hours.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard bivalirudin dosage for PCI?
The standard dosage for PCI is a 0.75 mg/kg intravenous bolus followed by a 1.75 mg/kg/hr continuous intravenous infusion during the procedure. An additional 0.3 mg/kg bolus may be considered if the ACT is below 225 seconds.
How is bivalirudin administered in patients with HIT?
In patients with HIT, bivalirudin is typically administered as a continuous intravenous infusion at a lower dose of 0.15-0.2 mg/kg/hr. A bolus is generally avoided in HIT. The infusion is continued until platelet recovery.
What dose adjustments are needed for renal impairment?
In patients with severe renal impairment (CrCl <30 mL/min), the bivalirudin infusion rate during PCI should be reduced to 1 mg/kg/hr. Dialysis-dependent patients require further dose reduction and close monitoring of ACT.
How quickly does bivalirudin's anticoagulant effect wear off?
Due to its short half-life of approximately 25 minutes, the anticoagulant effect of bivalirudin dissipates rapidly, typically within 1-2 hours of stopping the infusion in patients with normal renal function.
Is ACT monitoring required during bivalirudin administration?
ACT monitoring is typically performed during PCI to ensure adequate anticoagulation. The target ACT range varies depending on the specific protocol used by the institution. In HIT patients, ACT monitoring is less critical but may still be performed.
Can bivalirudin be used in patients with heparin allergy?
Yes, bivalirudin is a suitable alternative to heparin in patients with a known heparin allergy. It does not cross-react with heparin antibodies and does not cause HIT.

References

  1. 1
    Bivalirudin for percutaneous coronary intervention in acute coronary syndromes(2010)PubMed ↗
  2. 2
    Bivalirudin in patients with heparin-induced thrombocytopenia undergoing cardiac procedures(2009)PubMed ↗
  3. 3
    Pharmacokinetics and pharmacodynamics of bivalirudin in patients with renal impairment(2004)PubMed ↗

Last updated: 2026-02-19